Ischemic Stroke Clinical Trial
Official title:
Precise Antiplatelet THerapy Guided by Platelet Aggregation Function in Acute Ischemic STROKE
Objectives of Study:To explore the efficacy and safety of antiplatelet therapy in patients with non-cardiogenic cerebral infarction under the guidance of platelet aggregation function.
Non cardiogenic cerebral infarction accounts for more than 50% of cerebral infarction, and the key to its onset is an increase in platelet aggregation function. Aspirin is an IA recommended drug for the prevention and treatment of non cardiogenic cerebral infarction. However, after taking aspirin and clopidogrel regularly, more than 30% of stroke patients still experience ischemic events (aspirin resistance, clopidogrel resistance), leading to stroke recurrence. Aspirin is the main antiplatelet drug for the prevention and treatment of non cardiogenic cerebral infarction. Therefore, clinical research on aspirin resistance in the prevention and treatment of non cardiogenic cerebral infarction is of great significance, which can help partially solve the bottleneck of antiplatelet therapy resistance in cerebral infarction. Platelet aggregation function testing can timely detect resistance to antiplatelet therapy, guide drug adjustments, and researchers will compare the experimental group (receiving precise antiplatelet therapy) with the control group (blindly taking aspirin) to see if the experimental group will reduce stroke recurrence or mortality, in order to prevent and treat cerebral infarction with aspirin and clopidogrel resistance and reduce the recurrence rate of cerebral infarction. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05196659 -
Collaborative Quality Improvement (C-QIP) Study
|
N/A | |
| Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
| Completed |
NCT03281590 -
Stroke and Cerebrovascular Diseases Registry
|
||
| Recruiting |
NCT05518305 -
Platelet Expression of FcγRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosis
|
||
| Recruiting |
NCT06029959 -
Stroke and CPAP Outcome Study 3
|
N/A | |
| Recruiting |
NCT03728738 -
Zero Degree Head Positioning in Hyperacute Large Artery Ischemic Stroke
|
Phase 3 | |
| Terminated |
NCT03396419 -
IMPACT- 24col Collateral Blood Flow Assessment Following SPG Stimulation in Acute Ischemic Stroke (ImpACT-24B Sub-Study)
|
||
| Recruiting |
NCT05065216 -
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04897334 -
Transcranial Direct Current Stimulation and Rehabilitation to Ameliorate Impairments in Neurocognition After Stroke
|
N/A | |
| Not yet recruiting |
NCT06462599 -
Osteopontin Gene Polymorphism in Stroke Patients in Egypt
|
||
| Not yet recruiting |
NCT06026696 -
Cohort of Neurovascular Diseases Treated in the Acute Phase and Followed at Lariboisière
|
||
| Not yet recruiting |
NCT06032819 -
Differentiating Between Brain Hemorrhage and Contrast
|
||
| Recruiting |
NCT02910180 -
Genetic, Metabolic, and Growth Factor Repository for Cerebrovascular Disorders
|
||
| Completed |
NCT03554642 -
Walkbot Robotic Training for Improvement in Gait
|
Phase 3 | |
| Withdrawn |
NCT01866189 -
Identification of Hypoxic Brain Tissues by F-MISO PET in Acute Ischemic Stroke
|
N/A | |
| Completed |
NCT02922452 -
A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects
|
Phase 1 | |
| Recruiting |
NCT03041753 -
Reperfusion Injury After Stroke Study
|
N/A | |
| Completed |
NCT02549846 -
AdminiStration of Statin On Acute Ischemic stRoke patienT Trial
|
Phase 4 | |
| Completed |
NCT01678534 -
Reparative Therapy in Acute Ischemic Stroke With Allogenic Mesenchymal Stem Cells From Adipose Tissue, Safety Assessment, a Randomised, Double Blind Placebo Controlled Single Center Pilot Clinical Trial
|
Phase 2 | |
| Completed |
NCT02610803 -
Paroxysmal Atrial Fibrillation in Patients With Acute Ischemic Stroke
|
N/A |